PSNL
Personalis, Inc.
PSNL
Personalis, Inc.
Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly d
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK, July 21, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Personalis, Inc. (PSNL) M&A Call Transcript